Please login to the form below

chronic myeloid leukaemia

This page shows the latest chronic myeloid leukaemia news and features for those working in and with pharma, biotech and healthcare.

Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial

Drug improved major molecular response compared to existing med. Novartis experimental drug asciminib beat Pfizer’s Bosulif in a phase 3 trial in previously-treated chronic myeloid leukaemia (CML) patients, offering ... patients with newly diagnosed

Latest news

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Daurismo cleared for those too frail for chemo. Pfizer has added to a run of new product approvals for acute myeloid leukaemia (AML) with an FDA nod for Daurismo, the first ... indications such as myelodysplastic syndrome (MDS), acute lymphoblastic
FDA’s year-end approvals take annual tally to 46

Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... Patients with early (chronic) phase CML who have been taking Tasigna for three years or more and whose leukaemia has responded to
Novartis' orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients. Novartis has claimed another regulatory milestone for its chronic myeloid leukaemia (CML) drug Tasigna (nilotinib), winning approval for its use to treat children ... The European Commission approved
Takeda's gamble on Ariad pays off with Alunbrig approval

Iclusig - approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) - has been a slow-grower, largely because of safety concerns and while it has started to gain traction it
Takeda agrees $5.2bn deal to buy Ariad

Sale of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) therapy Iclusig for were pegged back by safety concerns that emerged in 2013 but since then have started to gain

More from news
Approximately 5 fully matching, plus 57 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

8. Daurismo – a new wave of AML treatment. After many years with no new therapies, the treatment of acute myeloid leukaemia (AML) is set for rapid change, thanks to a wave ... as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL),
Deal Watch January 2017

With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase
Deal Watch May 2016

In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and ... acute lymphoblastic leukaemia (ALL)] in Europe
Deal Watch table for December 2014

Research &licensing agreement. 142.5. Boston Heart Diagnostics / Eurofins Scientific. Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes. ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL,
Interview: Harvey Berger and Timothy Clackson, Ariad

December 2012 for its use in two rare types of cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... As for the future of Iclusig in leukaemia, Ariad is keen to roll out the drug in

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

Helen Parfitt joins Research Partnership

She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
Ariad founder Harvey Berger to retire as CEO and chairman

Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,
Hugh Cole leaves Shire for Ariad

This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.
Jonathan Dickinson joins Ariad from BMS

Will lead launch of chronic myeloid leukaemia treatment Iclusig. Ariad Pharmaceuticals has appointed Bristol-Myers Squibb's (BMS) Jonathan Dickinson as general manager of its European business. ... He joins at an important time for Ariad in Europe as it

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Spotlight interview: 15 minutes on patient-centricity in pharma

who are going through difficulties with mental health, living with chronic condition, pain management etc. ... We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017. .

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.